In September 2023, the FDA added BPC-157 to its Category 2 list of bulk drug substances under its Interim Policy on Compounding, meaning 503A compounding pharmacies and 503B outsourcing facilities are barred from using it in compounded preparations
Track: Weekly weight (same day, same time, same conditions) Measurements (waist, hips, chestmore reliable than scale alone) Side effects (what you feel, when, how severe) Food intake (even rough estimates help) PeptIQ makes this simplelog doses, track inventory, monitor your response over time
Such molecules may be appropriate for use at the first indication of mild cognitive impairment, and perhaps prophylactically in those individuals who are most likely to develop dementia due to genetic, health, behavioral and life-style predisposing factors
You can use the peptide reconstitution calculator to determine your preferred concentration
Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist currently in Phase 3 trials
Expert Insight / Pro Tip When designing an experimental protocol looking at tissue remodeling, remember that bpc-157 is highly dependent on active growth factor pathways
